Phase I Study of FXS887 in the Treatment of Solid Tumors

Summary

This is a single-arm, open-label, dose-escalation and dose-expansion Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of FXS887 in patients with advanced solid tumors. FXS887 is a innovative ATR inhibitors of a class of small-molecule inhibitors targeting ATR kinase.

Timeline

Start

2026-01-05

Primary completion

2027-04-28

Completion

2027-12-31

Drugs

Indications